AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00715559
Drug: cysteamine bitartrate
RxNorm normalized name: Cysteamine Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All enrolled participants will begin open treatment with cysteamine on the first visit of the experimental period (after screening, medical clearance and medication washout period if necessary). The dosing schedule is a flexible regimen starting at 150 mg PO three times daily. After one week, patients without intolerable side effects will increase the dose to 300 mg three times daily. The titration schedule will continue up to a maximum of 1800 mg a day. In case of adverse events, the investigator may decrease the dose by 150 mg daily.
Trial: NCT00604825
Drug: Other: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00616551
Drug: C2L-OCT-01 PR, 30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by deep IM injection (gluteus) on days 1 and 42
Trial: NCT00133809
Drug: Transplantation of Human Islets
RxNorm normalized name: microspheres of human albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure
Trial: NCT03205150
Drug: LIK066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated tablet of LIK066 either 30mg or 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84
Trial: NCT03205150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
Trial: NCT00675987
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 po QD
Trial: NCT03714763
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who show high expression of dopamine D2 receptors in PET-MR imaging will be treated with Cabergoline(CAB) tablets 2mg/week or bromocriptine(BC) tablets 7.5mg/ day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The medication will be stopped if failure to decrease tumor size and the subjects will be advised to surgical therapy.
Trial: NCT02182310
Drug: BI 201335 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01451398
Drug: Technosphere® Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technosphere® Insulin Inhalation Powder
Trial: NCT01451398
Drug: Technosphere Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT03430180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
Trial: NCT00305682
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 50mg/kg x 1 to be administered IV over 2 hours with high volume fluid flush on day -6.
Trial: NCT00065468
Drug: CCI-779
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of CCI-779 given Intra Venously once per week
Trial: NCT04047004
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional PIPAC with doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
Trial: NCT01874574
Drug: Hylan G-F 20
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
Trial: NCT01874574
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
Trial: NCT04349410
Drug: Hydroxychloroquine, Azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMTVDM Planar, SPECT, PET
Trial: NCT03028467
Drug: GSK3196165 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.
Trial: NCT04349410
Drug: Hydroxychloroquine, Doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMTVDM Planar, SPECT, PET
Trial: NCT03028467
Drug: GSK3196165 Dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.
Trial: NCT04349410
Drug: Hydroxychloroquine, Clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMTVDM Planar, SPECT, PET
Trial: NCT04349410
Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMTVDM Planar, SPECT, PET
Trial: NCT04349410
Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMTVDM Planar, SPECT, PET
Trial: NCT03028467
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate capsule/tablet 8-16 mg per week is given orally.
Trial: NCT00307099
Drug: Standard antibiotic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous antibiotic therapy for a minimum of 8 days.
Trial: NCT01648179
Drug: GSK1322322 (mesylate salt) Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg (mesylate salt) as free base, dissolved in sterile water for injection to a concentration of 100 mg/mL free base equivalent and sterilized via filtration. 15 mL of solution, equivalent to 1500 mg GSK 1322322, is the diluted into 0.9% Sodium Chloride Injection prior to infusion
Trial: NCT01648179
Drug: GSK1322322 (freebase) tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg tablets for a 1500 mg total single dose (3 tablets). Taken with 240 mL of water
Trial: NCT01648179
Drug: GSK1322322 (mesylate salt) Powder for Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg as a free base, dissolved in purified water to a concentration of 100 mg/mL free base equivalent. 15 mL of solution, equivalent to1500 mg GSK1322322 is administered orally with 225 mL of water
Trial: NCT01648179
Drug: GSK1322322 (freebase) tablets FED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug 500 mg tablets for a 1500 mg total single dose (3 tablets) (FED moderate fat meal) Taken with 240 mL of water
Trial: NCT03028467
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid tablet 5 mg per week is given orally.
Trial: NCT02749695
Drug: Melsmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placental extract Melsmon® (Japan): 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
Trial: NCT02525718
Drug: 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If randomized to this arm, subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine.~(2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively.
Trial: NCT00012324
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03395977
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose placebo for pills and saline for perfusion.
Trial: NCT02588105
Drug: AZD0156
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive AZD0156 as a monotherapy or in combination to assess safety and tolerability.
Trial: NCT02588105
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Module 2 combination with irinotecan/FOLFIRI
Trial: NCT00377637
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous cyclophosphamide (IVC) was administered every four weeks (monthly) to a total of six infusions.~Dosing was started at 0.75 g/m\^2 of body surface area for the first month, with subsequent doses at 0.5-1.0 g/m\^2. The target dose was 1.0 g/m\^2, but doses were titrated by 0.25 g/m\^2 increments to maintain nadir leukocyte count between 2500-4000/mm\^3.
Trial: NCT00377637
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg/kg/day orally, provided as 50 mg capsules to be taken after meals.
Trial: NCT00377637
Drug: Placebo to Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo capsules matching Azathioprine taken orally once a day.
Trial: NCT00377637
Drug: Placebo to Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo tablets matching Mycophenolate mofetil taken orally twice daily.
Trial: NCT00377637
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.
Trial: NCT01796028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01796028
Drug: TAXOTERE®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02942004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of matching placebo for either SAGE-547 60 μg/kg/h or 90 μg/kg/h.
Trial: NCT03186053
Drug: sodium creatine phosphate
RxNorm normalized name: Creatine phosphate
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sodium creatine phosphate .Loading dose followed by continuous infusion in operation
Trial: NCT01620268
Drug: Leflunomide and orotic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of leflunomide adjusted to target steady state blood levels of 50 ug/mL to 100 ug/mL of the active metabolite plus 600 mg orotic acid
Trial: NCT02754739
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin 40mg once daily for 24 weeks and nutritional education by a nutritionist
Trial: NCT02922153
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Institutional SOC for pain management will be followed.
Trial: NCT00334425
Drug: MENOPUR; GONAL-F
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04475848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: A placebo will be administered in an adaptive manner. The starting dose is planned to be 5 mg.~Part 2: The starting dose is planned to be 45 mg.
Trial: NCT04616872
Drug: Methotrexate-LDE
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX-LDE 40mg/m2 (250mL total volume) IV and Folic acid 5mg by mouth (the day after MTX-LDE) weekly for 12 weeks
Trial: NCT04616872
Drug: Placebo-LDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-LDE (250mL total volume) IV and Folic acid 5mg by mouth (the day after Placebo-LDE) weekly for 12 weeks
Trial: NCT00133562
Drug: Glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02380924
Drug: DSP loaded RBC using EryDex System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 10 mg DSP encapsulated in autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
Trial: NCT02380924
Drug: Sham treated RBC using the EryDex System
RxNorm normalized name: ANTICOAGULANT CPDA-1 THE CLX SYSTEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of sham treated autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
Trial: NCT00399191
Drug: stable isotope of iron, dysprosium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00687687
Drug: BSI-201 (Iniparib)
RxNorm normalized name: CENTRAL LINE DRESSING ERASE BSI CHANGE KIT MEDLINE #BSIPICC1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSI-201 will be administered IV over one hour twice weekly beginning on day 1 (doses of BSI-201 must be separated by at least 2 days).
Trial: NCT02334982
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-137 placebo-matching tablets
Trial: NCT00480402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a Placebo
Trial: NCT04341402
Drug: Antifungal Nail Gel Study
RxNorm normalized name: urea Topical Gel [Kera Nail]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Application antifungal gel of miconazole 3% and diclofenac sodium 1% and urea 40% to infected nails.
Trial: NCT00472810
Drug: MMC in glaucoma filtering surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If mitomycin -C is applied, a single cellulose sponge soaked with MMC (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
Trial: NCT02630108
Drug: EADM
RxNorm normalized name: ALCOHOL 69 mL in 100 mL TOPICAL GEL [Treadmill Doctor Advanced Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EADM is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: EADM 30-60 mg per patient,depending on the situation of the patient.
Trial: NCT02154464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004444
Drug: paromomycin
RxNorm normalized name: Paromomycin
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004444
Drug: streptomycin
RxNorm normalized name: Streptomycin
DrugBank: Streptomycin (DB01082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00962312
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02224625
Drug: 2% CHG Cloth solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational CHG
Trial: NCT00736905
Drug: TMC278
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04465500
Drug: Androgen Deprivation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosing and administration of ADT will be in accordance with the drug label for the drug(s) used for this purpose. Participants may receive ADT before and/or during the course of this study.
Trial: NCT03719430
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin is an anthracycline antibiotic with antineoplastic activity 75 mg/m2 IV day 1 (21 day cycles)
Trial: NCT00229437
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-128 placebo-matching tablets, orally, once daily for up to 6 months.
Trial: NCT00377442
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80mg po
Trial: NCT00162448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution, Oral, 0 mg, Single dose, 1 day.
Trial: NCT00249873
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration (tablets)
Trial: NCT01756989
Drug: Thalidomide, etoposide, celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide p.o. 1 mg/kg/day/1; the dose is gradually escalated, the maximum dose being 6 mg/kg/day. (The individual dose is set based on adverse effects.) Celecoxib p.o. 230 mg/m2/day/1-2, or in small children at 7 mg/kg/day in 1-2 doses.~Etoposide p.o. the initial dosage 20 mg/m2/day; the dose is gradually escalated, the maxi 70 mg/m2/day.
Trial: NCT01164202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 3cps/days 4 weeks over 6 during 1 year
Trial: NCT00958854
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03555487
Drug: 18F-choline PET
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mCi of 18F-FCH will be injected intravenously. PET imaging will be performed on PET/CT scanner. PET/CT from skull base to diaphragm will be started at 50 minutes after the injection.
Trial: NCT00555789
Drug: AEB071
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg oral b.i.d.
Trial: NCT00555789
Drug: mycophenolic plus tacrolimus
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 720mg b.i.d. 2yrs
Trial: NCT03098680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see arm/group descriptions
Trial: NCT00543218
Drug: calcitonin 100 IU/day subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05364918
Drug: Jeksung combined with anti-radiation spray
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat radiation stomatitis with Jeksung combined with anti-radiation spray
Trial: NCT03011866
Drug: Wound topically irrigated with 500mg TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03011866
Drug: 1mg/kg/hr TXA intravenous infusion till the last suture
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02306889
Drug: ANTARA® (fenofibrate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 130mg Capsules
Trial: NCT02254850
Drug: Mesoglycan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml.
Trial: NCT02254850
Drug: Mesoglycan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg.
Trial: NCT01816321
Drug: recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant FSH 300IU/daily from day 2 of the cycle (stimulation day 8)until day of ovulation triggering
Trial: NCT01816321
Drug: hp HMG
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hp HMG 300IU/daily from day 9 of the cycle (stimulation day 8)until day of ovulation triggering
Trial: NCT02254850
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.
Trial: NCT01232790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00468585
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03592888
Drug: mDC3/8-KRAS Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mature dendritic cell (mDC3/8) vaccine (primer and booster) in subjects with resected pancreatic adenocarcinoma
Trial: NCT02310074
Drug: Pulsatile Gonadotropin Releasing Hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02310074
Drug: Urinary Follicle-Stimulating Hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary Follicle-Stimulating Hormone (uFSH)
Trial: NCT02945826
Drug: One injection of 68Ga-NOTA-AE105
RxNorm normalized name: Gel-One Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection of 68Ga-NOTA-AE105
Trial: NCT01477762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo tablet will be taken ten hours prior to completing study assessments.
Trial: NCT02254850
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
Trial: NCT00313846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.
Trial: NCT03508102
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the effects of remifentanil on the average value of BIS at the time period of before induction , induction , intubation , skin incision, peritoneum incision, uterine incision, and delivery
Trial: NCT01800045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule in the morning before breakfast